In the following video, Motley Fool health-care analyst David Williamson takes investors through one possible boom for Eli Lilly , and one major potential bust. The company does have several major catalysts coming in the near term for drugs in its pipeline aimed both at stomach cancer and diabetes, but will these be enough to counteract losses from a major patent cliff coming up for the company? David gives his opinion on Eli's pipeline, and just how bad the patent cliff could be.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
The article Eli Lilly's Boom-or-Bust Potential originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.